Enlivex Therapeutics Ltd
Research Enlivex Therapeutics Ltd (ENLV) on Bullrun: market cap USD 363.76M, P/E 0.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerENLV
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 363.76M
- P/E0.0
- Financial periodFY2025
- RevenueUSD 0
- Net incomeUSD 1.24B
- Free cash flow-USD 10.48M
Valuation Snapshot
latest market cap is USD 363.76M; P/E is 0.0.
Peer valuation comparison
Latest P/E is 0x versus a Healthcare sector median of 24.46x (100.0% below).
Latest P/E is 0x versus a Israel median of 24.26x (100.0% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | USD 1.24B | -USD 10.48M | n/a | 25.48 | USD 1.89M | USD 641.00K | USD 1.93B |
| FY2024 | USD 0 | -USD 15.01M | -USD 13.11M | n/a | -0.73 | USD 3.30M | USD 534.00K | USD 23.59M |
| FY2023 | n/a | -USD 29.07M | -USD 23.76M | n/a | -1.56 | USD 813.00K | USD 1.03M | USD 30.08M |
| FY2022 | n/a | -USD 31.06M | -USD 32.08M | n/a | -1.69 | USD 49.95M | USD 299.00K | USD 56.84M |
| FY2021 | n/a | -USD 14.47M | -USD 19.17M | n/a | -0.81 | USD 11.20M | USD 10.00M | USD 85.04M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 363.76M | 0.0 | n/a | n/a |
| 2025 | 2025-12-31 | USD 166.17M | 0.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 27.67M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 50.22M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 72.54M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 114.57M | n/a | n/a | n/a |
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Enlivex Therapeutics Ltd's market cap?
Enlivex Therapeutics Ltd's market capitalization is USD 363.76M.
What is Enlivex Therapeutics Ltd's P/E ratio?
Enlivex Therapeutics Ltd's price-to-earnings (P/E) ratio is 0.0.
What does Enlivex Therapeutics Ltd do?
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd.